Artificial pancreas improves the treatment of type 1 diabetes

The first world clinical trial by comparing three treatments for type 1 diabetes supports the results of a previous study, and confirms that an artificial pancreas, essentially external, improves glucose control and reduces the risk of hypoglycemia, compared to the treatment ofDiabetes by insulin pump.

This new clinical trial has been carried out by a team of specialists from the Institute of Clinical Research of Montreal (IRCM) and the University of Montreal, both institutions in Canada, led by the endocrinologist Dr. Rémi Rabasa-Lhoret.The results are encouraging and could have important repercussions on the treatment of type 1 diabetes, a chronic disease that can cause loss of vision and cardiovascular problems.

Artificial pancreas is an automated system that reproduces, to some extent, the work of a natural pancreas in good condition, continuously adapting insulin release to changes in glucose levels.The artificial pancreas has two configurations: one in which only insulin releases, and another in which insulin and glucagon releases.

External artificial pancreas: left, constant glucose surveillance device.The pump, holds in the belt, injects insulin under the patient's skin, to the right.The control system is in this case a smartphone or smartph

While insulin lowers blood glucose levels, glucagon has the opposite effect and elevates them.

People with type 1 diabetes should carefully control their blood glucose levels so that they remain within normal values.Blood glucose control is the key to avoiding long -term complications related to high glucose levels (such as blindness or renal failure) and reduce the risk of hypoglycemia (dangerously low blood glucose levels, which can cause confusion, disorientation, disorientation, and even loss of consciousness in severe cases).

The new clinical trial shows that in its two configurations the artificial pancreas improves glucose control and reduces the risk of hypoglycemia, compared to treatments based on an insulin pump.

The next step in this line of research and development will be to perform clinical trials with larger amounts of patients and during longer test periods.If no unexpected difficulty arises, technology should be commercially available within the next 5 to 7 years.

It is estimated that 285 million people around the world are affected by diabetes, and that approximately 10 percent of them suffer from type 1. taking into account the number of new cases of diabetes each year, it is estimated that the number ofAffected will reach 438 million around 2030, giving epidemic dimensions to this problem.

Ahhhhhhhhhhhhhh available in 5 or 7 years ..................

HOPEFULLY.

How ambitious is people, wait 7 years for this device shit.I would not want or give it away.

If this nonsense (it is a simple insulin pump that communicates with an interstitial sensor) is already available and for sale today, in Australia.

YouTube.com/watch?v=WL6WDKXXJBC

Thanks for the "little ambitious", they usually call me dreamer, utopian, etc.

The only thing that speaks the link you have placed is that with the Medtronic pump and a continuous meter if the meter detects a hypo the pump stops infusing insulin.Nothing else.Ah, and they also have it in Spain, it is not necessary to go to Australia,

What I want, if the cure cannot be, is an apparatus that does everything alone, without me having to think absolutely, and with which you get good glycemic results.I think that this is what Fer has posted fromThat I want to prescribe it to my endocrine ... well, that will always be an unknown, so savings and in 5-7 years I hope to forget the m of diabetes.It is my little ambition in life ;-)

Well, how much nonsense, the Medtronic that, anyway with the technology of the interstitial sensors that go 15 minutes late and the time it takes to arrive in the injected insulin (by pump or by boli) between 15-30 more that must be added.It is impossible for him to do everything with good glymatical results.You will always have to say before eating exactly how many HC you will eat.Even with the so -called "artificial pancreas" of this article that carries insulin and glucagon.

In addition, in a photo that posted in another thread on this, it was seen that the fantastic control of this "pancreas" is equivalent to being almost all day above 200.

And sincerely I prefer a thousand times to control the diabetes myself, to have to carry one or two cables always stuck in the skin and a device hanging from them.

Hello,
I have used the 530g of Medtronic with a Enlite sensor.I didn't like it.The idea is magnificent, but Medtronic's sensors are not precise.The pumps stop putting insulin every time the sensor detects a 60 (without response from the person who carries it), but as the sensor detects a 60 when sometimes one is in 140, because the system is useless.The artificial pancreas is much more sophisticated than that, although it will not be for everyone.Unfortunately it will cost a kidney and a half and there will always be those who prefer to continue with the bolis.For tastes colors.The PA does not keep you in 200 all day, but in 100 (or in the numbers that one determines).Correct basal and apply insulin bowling according to the prediction of glycemia at 4 hours and it is suspended if it detects the arrival of hypoglycemia.The PA will still need the innervention of the person who carries it: hydrates account, decisions regarding exercise, disease plans, etc.But the time will decrease that, those well controlled dedicate them to think about the disease (about two hours a day is a barbarity of time).
As for the 530g of Medtronic, I returned it to his house and passed Dexcom and the Nightscout piracy (what a great invention!), Which has unique accuracy and that keeps me with a hemoglobin of 5.8.With this new sensor it can begin to think about a brilliant future for diabetes, even in a few years.

Here is a photo of a participant in the artificial pancreas essay.
Link style = "Max-Width: 300px;

You can see how most of the this day above 200